Status:
COMPLETED
Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies
Lead Sponsor:
Sohag University
Conditions:
Endometrial Hyperplasia
Endometrial Adenocarcinoma
Eligibility:
FEMALE
15+ years
Brief Summary
endometrial hyperplasia may progress to endometrial adenocarcinoma. the exact possibility of such progression is not determined. there a need to detect biological markers that can help in detecting hi...
Detailed Description
Adenocarcinoma of the endometrium is the most prevalent invasive tumor of female genital tract. Endometrial carcinoma is divided to 2 different types as regards to genitical and phenotypical features,...
Eligibility Criteria
Inclusion
- all cases of endometrial biopsies and hystrectomy specimens diagnosed as endometrial hyperplasia and/or primary endometrial adenocarcinoma.
- all cases of normal endometrium obtained from hystrectomy specimens due to other pathological conditions as prolapsed uteri, uterine leiomyoma and adenomyosis.
Exclusion
- autolysed samples, very tiny specimens cervical tissues and specimens with histological picture of endometritis.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04873206
Start Date
January 1 2020
End Date
December 31 2020
Last Update
July 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maisa Hashem Mohammed
Sohag, Egypt, 82524